Marcela V. Maus

Featured in: Favicon

nature.com Favicon

wiley.com

cell.com

thelancet.com Favicon

healio.com Favicon

newsbreak.com Favicon

aacrjournals.org Favicon

jbc.org

cgtlive.com Favicon

onlinelibrary.wiley.com + 1 more

Articles

CAR-T cell therapy for the treatment of adult high-grade gliomas | npj Precision Oncology

Dec 19, 2024 | nature.com | Sangwoo Park |Marcela V. Maus |Bryan Choi

Treatment for malignant primary brain tumors, including glioblastoma, remains a significant challenge despite advances in therapy. CAR-T cell immunotherapy represents a promising alternative to conventional treatments. This review discusses the landscape of clinical trials for CAR-T cell therapy targeting brain tumors, highlighting key advancements like novel target antigens and combinatorial strategies designed to address tumor heterogeneity and immunosuppression, with the goal of improving outcomes for patients with these aggressive cancers.
Tracking non-relapse mortality after CAR T cell therapy - Nature Medicine

Aug 30, 2024 | nature.com | Marcela V. Maus

Infections account for the highest number of non-relapse-related deaths after CAR T cell therapy, underscoring the necessity for clinical risk-mitigating strategies and a deeper understanding of CAR T cell-related cytopenia.
FDA reduces risk reporting for CAR T cells to ‘minimize the burden’ on providers

Aug 15, 2024 | healio.com | Drew Amorosi |Mindy Valcarcel |Marcela V. Maus

You've successfully added Leukemia to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. FDA has scaled back its Risk Evaluation and Mitigation Strategy reporting requirements for providers of chimeric antigen receptor T-cell therapies.
FDA reduces risk reporting for CAR T cells to ‘minimize the burden’ on providers

Jul 2, 2024 | healio.com | Drew Amorosi |Mindy Valcarcel |Marcela V. Maus

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. FDA has scaled back its Risk Evaluation and Mitigation Strategy reporting requirements for providers of chimeric antigen receptor T-cell therapies.
Novel multi-engineered CAR-T shows significant, rapid reduction of aggressive brain tumor

Mar 14, 2024 | healio.com | Josh Friedman |Mindy Valcarcel |Marcela V. Maus

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Multi-engineered CAR-T drastically reduced tumor size of glioblastoma in a phase 1 trial. Future research aims to extend response time.
Marcela Maus, MD, PhD, on New Research on CAR T for Solid Tumors, Glioblastoma

Feb 13, 2024 | cgtlive.com | Marcela V. Maus

“I feel like the field has fits and starts in terms of which diseases and which trials end up being positive. There are always some surprises that come along. And I think that's kind of where we are with solid tumor. The field started in ovarian cancer, there's been trials in pancreatic cancer and mesothelioma, and we're starting to see some evidence of responses, but what seems to be taking off is soft tissue sarcomas and neuroblastomas and potentially gliomas.
Marcela Maus, MD, PhD, on New Questions With CAR-T's Rise in Solid Tumors

Feb 1, 2024 | newsbreak.com | Marcela V. Maus

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
Marcela Maus, MD, PhD, on New Questions With CAR-T's Rise in Solid Tumors

Feb 1, 2024 | cgtlive.com | Marcela V. Maus

“With CAR T therapy, I think we're right on the cusp. Things are looking promising. It may not be with the tumors that everyone expected it to be in. And I think we're going to learn a lot as these trials move forward, about, what the best dosing and schedule is for CAR T, how we give them in combinations, what are the long-term toxicities? What's the durability, what levels of engraftment? What levels of persistence?
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening - Nature Communications

Dec 4, 2023 | nature.com | Keene L. Abbott |Audrey J. Muscato |Kathleen B. Yates |Juan Dubrot |John G. Doench |Marcela V. Maus | +3 more

AbstractCAR-T therapy is a promising, novel treatment modality for B-cell malignancies and yet many patients relapse through a variety of means, including loss of CAR-T cells and antigen escape. To investigate leukemia-intrinsic CAR-T resistance mechanisms, we performed genome-wide CRISPR-Cas9 loss-of-function screens in an immunocompetent murine model of B-cell acute lymphoblastic leukemia (B-ALL) utilizing a modular guide RNA library.
Marcela Maus, MD, PhD, on New Approaches to CAR T-Cell Therapy for Solid Tumors

Nov 30, 2023 | cgtlive.com | Marcela V. Maus

“I think that there's a lot of interesting approaches. I like the dual targeted, next gen approaches, but those are also a little bit earlier in development and in time... It's not like the Olympics where there's a single winner. It's like a marathon with lots of different people running ina race, and there's all sorts of different divisions and winners in the whole thing.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Marcela V. Maus

Articles

CAR-T cell therapy for the treatment of adult high-grade gliomas | npj Precision Oncology

Tracking non-relapse mortality after CAR T cell therapy - Nature Medicine

FDA reduces risk reporting for CAR T cells to ‘minimize the burden’ on providers

FDA reduces risk reporting for CAR T cells to ‘minimize the burden’ on providers

Novel multi-engineered CAR-T shows significant, rapid reduction of aggressive brain tumor

Marcela Maus, MD, PhD, on New Research on CAR T for Solid Tumors, Glioblastoma

Marcela Maus, MD, PhD, on New Questions With CAR-T's Rise in Solid Tumors

Marcela Maus, MD, PhD, on New Questions With CAR-T's Rise in Solid Tumors

Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening - Nature Communications

Marcela Maus, MD, PhD, on New Approaches to CAR T-Cell Therapy for Solid Tumors

Contact details

Emails

Socials & Sites